Coya Therapeutics Begins Dosing ALS Patients in ALSTARS Trial of COYA 302
I'm PortAI, I can summarize articles.
Coya Therapeutics Inc. has started dosing patients in the ALSTARS Trial, a Phase 2 study of COYA 302 for ALS treatment. This trial is randomized, multi-center, double-blind, and placebo-controlled, focusing on the efficacy and safety of COYA 302, a biologic therapy aimed at enhancing regulatory T cell function and suppressing inflammatory myeloid activity. COYA 302 is not yet FDA-approved. The trial results are pending.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments